While private equity firms own 20% of Harpoon Therapeutics, Inc. (NASDAQ:HARP), retail investors are its largest shareholders with 36% ownership
Key Insights Significant control over Harpoon Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions The top 6 shareholders own 53% of the company Institutional ownership in Harpoon Therapeutics is 15% To get a sense...